Skip to content
Medx

Tag: Sonidegib

Explore our medication guides and pharmacology articles within this category.

What is Odomzo (Sonidegib)? A Guide to This Targeted Cancer Medication

•
3 min read
In clinical trials for locally advanced basal cell carcinoma (laBCC), the targeted therapy Odomzo (sonidegib) demonstrated an objective response rate of 56% for patients receiving the 200 mg daily dose. Approved by the FDA, **what is Odomzo** and how does this medication work to treat certain types of skin cancer?

When to take ODOMZO: Understanding Administration Guidelines

•
3 min read
In clinical studies, the objective response rate for patients with locally advanced basal cell carcinoma (laBCC) taking ODOMZO was 58%. To ensure maximum effectiveness and minimize side effects, it is crucial to understand the proper administration schedule, including when to take ODOMZO relative to meals and what to do for a missed dose.